Image source: The Motley Fool.Wednesday, May 28, 2025 at 8:30 a.m. ETPresident and Chief Executive Officer - Peter FitzsimmonsContinue reading ...

LOS ANGELES, May 28, 2025 ( GLOBE NEWSWIRE ) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.

Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses In Ibotta To Contact Him Directly To Discuss Their Options

"Nordics are walking back the cashless society initiative because their centralized implementation of the concept is too fragile," Buterin said.

Oklo voiced support for a slate of new executive orders issued by the White House aimed at boosting advanced nuclear energy adoption. Discover how Matt Maley trades sharp reversals-live this Wednesday, May 28 at 6 PM ET. Save your free seat now. Oklo Inc.

A note from Kelly Moneymaker, AIFF Humanitarian Award Recipient 2024 and owner of Alaska-based Drum Song Films ANCHORAGE, Alaska, May 28, 2025 /PRNewswire/ -- I'm incredibly honored to join the AIFF ( Anchorage International Film Festival ) Board of Directors, alongside the brilliant and ...

Motorola Solutions will acquire Silvus Technologies for up to $5.0 billion, including $4.4 billion cash and up to $600 million earnouts. The acquisition of Silvus' MANET technology aims to boost Motorola Solutions' secure communications offerings for defense and public safety.

Market volatility over the past few months could lead investors to sell and take their winnings home before things get worse. But investing success means riding out the short-term waves and holding on to long-term winners.

Dick's Q1 comps rose 4.5%, driven by higher ticket size and transactions. Company reaffirmed FY2025 EPS and sales guidance despite Q1 miss. Discover how Matt Maley trades sharp reversals-live this Wednesday, May 28 at 6 PM ET. Save your free seat now.

The trial stopped early after meeting the primary endpoint in 1,690 hospitalized adults with cUTIs. No new safety concerns were found; diarrhea and headache were the most common side effects. Unlock your all-in-one trading dashboard with real-time alerts, rankings, and stock ideas-now 60% off ...